Dr Reddy’s and Sanofi partner to launch Beyfortus, a novel drug to prevent respiratory syncytial virus in infants.

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring its effectiveness, according to Yale research published in JAMA Network Open.

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...

GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on ...

The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60 to 74 at high risk ...

ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides effective protection against respiratory syncytial virus-related lower respiratory ...